Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Joseph Nkolola"'
Autor:
Martina S. Wesley, Kelvin T. Chiong, Kelly E. Seaton, Christine A. Arocena, Sheetal Sawant, Jonathan Hare, Kasey Hernandez, Michelle Rojas, Jack Heptinstall, David Beaumont, Katherine Crisafi, Joseph Nkolola, Dan H. Barouch, Marcella Sarzotti-Kelsoe, Georgia D. Tomaras, Nicole L. Yates
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
The outcome of the recent Antibody Mediated Prevention (AMP) trials that tested infusion of the broadly neutralizing antibody (bnAb) VRC01 provides proof of concept for blocking infection from sensitive HIV-1 strains. These results also open up the p
Externí odkaz:
https://doaj.org/article/d63aa843b5a34a67943c882fbac2631d
Autor:
Kathryn E Stephenson, Michael C Keefer, Catherine A Bunce, Doreen Frances, Peter Abbink, Lori F Maxfield, George H Neubauer, Joseph Nkolola, Lauren Peter, Christopher Lane, Harriet Park, Carl Verlinde, Angela Lombardo, Christopher Yallop, Menzo Havenga, Patricia Fast, John Treanor, Dan H Barouch
Publikováno v:
PLoS ONE, Vol 13, Iss 11, p e0205139 (2018)
BACKGROUND:Live, attenuated viral vectors that express HIV-1 antigens are being investigated as an approach to generating durable immune responses against HIV-1 in humans. We recently developed a replication-competent, highly attenuated Ad26 vector t
Externí odkaz:
https://doaj.org/article/84ce77595dcb493e882e2490cef97506
Autor:
Anne-Sophie Dugast, Ying Chan, Michelle Hoffner, Anna Licht, Joseph Nkolola, Hualin Li, Hendrik Streeck, Todd J Suscovich, Musie Ghebremichael, Margaret E Ackerman, Dan H Barouch, Galit Alter
Publikováno v:
PLoS ONE, Vol 9, Iss 5, p e97229 (2014)
Recent immune correlates analysis from the RV144 vaccine trial has renewed interest in the role of non-neutralizing antibodies in mediating protection from infection. While neutralizing antibodies have proven difficult to induce through vaccination,
Externí odkaz:
https://doaj.org/article/a3af037709d04423b28265a7eeaede41
Autor:
Boris Julg, Kathryn E. Stephenson, Kshitij Wagh, Sabrina C. Tan, Rebecca Zash, Stephen Walsh, Jessica Ansel, Diane Kanjilal, Joseph Nkolola, Victoria E. K. Walker-Sperling, Jasper Ophel, Katherine Yanosick, Erica N. Borducchi, Lori Maxfield, Peter Abbink, Lauren Peter, Nicole L. Yates, Martina S. Wesley, Tom Hassell, Huub C. Gelderblom, Allen deCamp, Bryan T. Mayer, Alicia Sato, Monica W. Gerber, Elena E. Giorgi, Lucio Gama, Richard A. Koup, John R. Mascola, Ana Monczor, Sofia Lupo, Charlotte-Paige Rolle, Roberto Arduino, Edwin DeJesus, Georgia D. Tomaras, Michael S. Seaman, Bette Korber, Dan H. Barouch
Publikováno v:
Nature medicine. 28(6)
HIV-1 therapy with single or dual broadly neutralizing antibodies (bNAbs) has shown viral escape, indicating that at least a triple bNAb therapy may be needed for robust suppression of viremia. We performed a two-part study consisting of a single-cen
Autor:
Ronald R. Cobb, Joseph Nkolola, Pavlo Gilchuk, Abishek Chandrashekar, Jingyou Yu, Robert V. House, Christopher G. Earnhart, Nicole M. Dorsey, Svetlana A. Hopkins, Doris M. Snow, Rita E. Chen, Laura A. VanBlargan, Manuel Hechenblaickner, Brian Hoppe, Laura Collins, Milan T. Tomic, Genevieve H. Nonet, Kyal Hackett, James C. Slaughter, Mark G. Lewis, Hanne Andersen, Anthony Cook, Michael S. Diamond, Robert H. Carnahan, Dan H. Barouch, James E. Crowe
Publikováno v:
Med (New York, N.y.)
Background Human monoclonal antibody (mAb) treatments are promising for COVID-19 prevention or therapy. The pre-exposure prophylactic efficacy of neutralizing antibodies that are engineered with mutations to extend their persistence in human serum an